{"id":2386,"date":"2025-01-10T16:42:40","date_gmt":"2025-01-10T13:42:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2386"},"modified":"2025-11-03T20:30:56","modified_gmt":"2025-11-03T17:30:56","slug":"plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics\/","title":{"rendered":"Dyne Therapeutics annonce des projets pour DYNE-101 dans la DM1 et DYNE-251 dans la DMD"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Dyne Therapeutics a annonc\u00e9 des donn\u00e9es cliniques positives pour ses th\u00e9rapies DYNE-101 et DYNE-251 lors d&#039;un \u00e9v\u00e9nement destin\u00e9 aux investisseurs le 10 janvier 2025. DYNE-101 pour la dystrophie myotonique de type 1 (DM1) a d\u00e9montr\u00e9 une correction d&#039;\u00e9pissage significative et des am\u00e9liorations fonctionnelles, ce qui a conduit Dyne \u00e0 planifier une cohorte d&#039;expansion d&#039;enregistrement mondiale de l&#039;essai ACHIEVE avec une dose d&#039;enregistrement de 6,8 mg\/kg Q8W et une soumission potentielle d&#039;approbation acc\u00e9l\u00e9r\u00e9e aux \u00c9tats-Unis au premier semestre 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Parall\u00e8lement, le DYNE-251, qui cible la dystrophie musculaire de Duchenne (DMD), poursuit \u00e9galement une approbation acc\u00e9l\u00e9r\u00e9e aux \u00c9tats-Unis bas\u00e9e sur la dystrophine comme crit\u00e8re d&#039;\u00e9valuation de substitution, avec des donn\u00e9es attendues d&#039;ici fin 2025 pour soutenir une soumission d\u00e9but 2026. Les deux programmes semblent prometteurs pour transformer les paradigmes de traitement de ces maladies g\u00e9n\u00e9tiques.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg\/kg Q8W [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2388,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[118,66,143,144,145],"class_list":["post-2386","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duchenne","tag-duchenne-muscular-dystrophy","tag-dyne","tag-dyne-101","tag-dyne-251"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=2386"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/2388"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=2386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=2386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=2386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}